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Abstract
Iron is an essential element for all living organisms. Iron metabolism is mainly
controlled by its absorption. Iron deficiency (ID) is the most common nutritional
deficiency, causing important clinical outcomes. One of the most common results of
ID is iron deficiency anemia (IDA). The ID results from increased physiological needs,
blood losses, inadequate intake, and diminished absorption. Helicobacter pylori (H.
pylori) infection is one of the important causes of IDA, especially in undetermined and
refractory cases.
In the literature, case series, sero-epidemiological studies, and meta-analyses showed
robust evidence about the relationship between IDA and H. pylori. Several mecha‐
nisms have been proposed for IDA in H. pylori infection. In this chapter, we review
clinical evidence regarding the relationships between H. pylori and IDA, iron
metabolism, possible mechanisms of IDA in H. pylori infection, factors involved in
IDA development in H. pylori infection, and IDA management in H. pylori infection.
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1. Introduction
Iron (Fe) is an essential element for hemoglobin synthesis, oxidation–reduction reactions, and
cellular proliferation. The term iron deficiency (ID) describes a deficit in total body iron,
resulting in reduction of serum ferritin levels below normal limit [1]. ID is the most frequent
nutritional deficiency worldwide.
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ID is associated with impaired cognitive function, diminished work productivity, and
behavioral problems in adults and children. In pregnant women, ID has been linked with
increased risk for low birth weight, prematurity, and maternal morbidity [2].
Iron deficiency anemia (IDA) is defined as low hemoglobin and plasma ferritin values caused
by further decrease in iron stores. IDA is the most common form of anemia worldwide with a
prevalence varying from 2% to 8% in developed countries. IDA may occur at all stages of the
life cycle, but it is more prevalent in mothers and young children [3].
The known causes of ID are inadequate dietary intake, increased physiological needs as seen
in pregnancy and children during rapid growth, increased losses such as bleeding or hemol‐
ysis, and diminished iron absorption as seen in celiac disease and chronic inflammatory
diseases [4, 5]. Because IDA can result from both physiological and pathological events, the
etiology underlying IDA should be determined. The exact cause could not be identified in 20%
of cases, despite all routine examinations including gastrointestinal endoscopy and serologic
markers for celiac disease [3].
Helicobacter pylori (H. pylori) infection has been proven as a cause of IDA, especially in unde‐
termined cases. Exact mechanism for IDA in H. pylori infection is still unclear. However, several
mechanisms have been proposed to explain the relationship between H. pylori infection and
IDA, including gastrointestinal bleeding and bacterial competition for dietary iron and
subversion of the human iron regulatory mechanism [6]. In this chapter, we review clinical
evidence regarding the relationship between H. pylori and IDA, iron metabolism, possible
mechanisms of IDA in H. pylori infection, factors involved in the development of IDA in H.
pylori infection, and IDA management in H. pylori infection
2. Clinical evidences on the relationship between iron deficiency anemia
and H. pylori
The relationship between H. pylori and IDA was first described by Blecker et al. in 1991. Authors
described a 15-year-old patient with IDA due to H. pylori-positive chronic active hemorrhagic
gastritis without prior gastrointestinal manifestations. Hemoglobin value and serum ferritin
level of the patient returned to normal limits unless administration of supplementary iron,
after the infection was eradicated [7]. Subsequently, Bruel et al. in 1993 reported a second IDA
case (hemoglobin 5.6 g/dL) in an 11-year-old child with H. pylori infection complicated with
severe digestive hemorrhage. The anemia resolved after the eradication of the H. pylori
infection without iron replacement [8]. In the same year, the first case with refractory IDA
without the symptomatic gastrointestinal pathology was reported in a 7-year-old child by
Dufour et al., in which H. pylori infection was diagnosed. After the infection was eradicated
without supplementary iron treatment, improvement in hematological parameters was
observed on month six [9].
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Following above-mentioned reports [7-9], further isolated case reports were published in both
adolescents and adults in the literature during the 1990s, indicating an association between
IDA and H. pylori with therapeutic response after H. pylori eradication [10-13].
These preliminary case series in the literature encouraged the epidemiologic studies regarding
the association between H. pylori and IDA. While some studies showed an association between
H. pylori and IDA among women [14], the other studies showed differences in serum iron levels
among H. pylori-infected men [15]. In another large cross-sectional study, it was found that H.
pylori infection was associated with reduction in serum ferritin levels and that this association
seemed stronger among adolescents and women at childbearing age [16]. Most epidemiologic
studies had cross-sectional design. However, national health surveys enhanced the results of
previous reports. Among these, a German study [17] on adult population found a decrease in
serum ferritin levels by 16% in individuals infected with H. pylori [17]. In addition, children
and adolescents were also studied in population-based surveys in South Korea [18-20].
Likewise, these studies showed an association between H. pylori and ID. A recent German
study on pregnant women reported an association between current H. pylori infection and
hemoglobin levels [21].
In this category, the largest study was conducted on 7,462 participants aged >3 years from the
1999–2000 National Health and Nutrition Examination Survey (NHANES). The study showed
that H. pylori infection diagnosed by serology is associated with an increase by 40% in the
prevalence of ID in the United States [22].
Finally, meta-analyses have supported the association between H. pylori infection and IDA
[23-27]. Furthermore, resolution of iron deficiency anemia has been shown following the
successful eradication of H. pylori [26].
All these publications have supported the relationship between H. pylori and IDA.
3. Regulation of iron balance
Steps in iron metabolism and contributing molecules are important for understanding effect
of H. pylori infection on IDA.
Body iron metabolism is a semi-closed system and is critically regulated by several factors.
The total amount of body iron is approximately 3–4 g. Two thirds of iron is found in the pool
of red blood cell (RBC) and recycled by RBC destruction; the remainder is stored. Only 1–2 mg
of iron is absorbed from intestinal tract and circulated in the blood. Since, there is no active
mechanism to excrete iron from the body, iron balance is controlled by absorption [1].
Nearly all absorption of dietary iron occurs in the duodenum. Steps involved in iron metab‐
olism include the reduction of iron into a ferrous state (Fe2+), apical uptake, intracellular storage
or transcellular trafficking, and basolateral release. Several proteins play a role in these steps
[Table 1].
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Function Protein
Enzyme Ferri-reductase
Hemeoxygenase-1 (HO-1)
Transport Divalent metal transporter-1 (DMT-1)
Lipocalin-2
Ferroportin-1
Heme-carrier protein-1
Transferrin
Transferrin receptor 1 / 2
Natural resistance associated macrophage protein-1
Hephaestin
Storage Hemosiderin
Ferritin
Lactoferrin
Regulatory Iron regulatory protein 1/2 (IRP)
Iron regulatory elements (IRE)
Hepcidin
Table 1. Proteins Involved in Iron Metabolism
Dietary iron is found in two forms; heme iron (10%) that is derived from meat and bound to
hemoglobin (Hb) and myoglobin and nonheme iron (90%) that is ionic and inorganic in form
derived from plants (Figure 1). Both iron forms are absorbed at the apical surface of duodenal
cells through different mechanisms.
Nonheme iron taken on a diet presents initially in oxidized (ferric-Fe3+) form. This form of iron
is not bioavailable, and before it is absorbed by an enterocyte it needs to be reduced to the
Fe2+ form via ferri-reductase enzyme [28]. Fe3+ reduction is optimized by low gastric pH. Gastric
acid, dietary ascorbic acid, and luminal reductases enhance the iron absorption [29]. Iron is
transported across the intestinal epithelium by a transporter called divalent metal transport‐
er-1 (DMT-1) that also transports other metal ions by a proton-coupled mechanism [30] (Figure
1). There is also a siderophore-like iron uptake pathway mediated by lipocalin-2 that seems to
exert an innate immune response against bacterial infection by sequestrating iron. However,
physiological role of lipocalin-2 has not been fully elucidated.
Heme iron is better absorbed than nonheme form. Heme iron is absorbed into enterocytes by
heme carrier protein-1 that is a membrane protein found in the proximal intestine [31] (Figure
1). Heme iron is degraded by hemeoxygenase-1 (HO-1) within enterocyte [32] (Figure 1).
In the intestinal epithelial cell, iron can follow two pathways. Firstly, it may remain in the cell
to be used or stored. This iron is excreted when intestinal cells demise and are molted into the
lumen. Secondly, iron is transported into circulation from basolateral membrane of the
enterocyte. This part is called absorbed iron. Ferroportin-1 is the sole supposed iron exporter
that has been defined so far. Fe2+ is transported from the basal membrane via ferroportin-1;
Extradigestive Manifestations of Helicobacter Pylori Infection - An Overview116
thereafter, it is oxidized into Fe3+ by a multi-copper-oxidase protein called hephaestin, an
enzymatic protein similar to plasma ceruloplasmin, before being bound by plasma transferrin
(Tf). Ferroportin-1 is also the putative iron exporter in macrophages and hepatocytes [1, 28].
Iron absorption, mediated by two models, is up-regulated by iron deficiency and increased
erythropoiesis or down-regulated in inflammation and iron repletion. These two models can
be entitled as crypt programming model and the hepcidin model.
The crypt programming model: The intracellular iron level of the duodenal crypt cells
intercommunicate with the iron deposits of the body, which, in turn, establishes the amount
of iron absorbed from the intestinal lumen. The crypt cells express both transferrin receptor-1
(TfR1) and TfR2. The cellular uptake of Tf-bound iron from plasma is mediated by these
receptors [28, 33].
TfR1 is expressed pervasively and Tf-mediated iron uptake is proposed to take place in
majority of the cell types. Despite that, expression of TfR2 is limited in hepatocytes, duodenal
crypt cells, and erythroid cells, suggesting a more privatized mission in iron balance.
Iron regulatory elements (IREs) act as iron sensors and regulate translation or stability of
mRNA-encoding proteins. The intracellular iron level commands the interaction of IREs with
cytosolic iron regulatory proteins (IRPs) 1 and 2. In the absence of iron, IRP1 binds to IREs of
TfR1, DMT-1, and ferroportin-1 mRNA; then, syntheses of these proteins begin in the duode‐
num and dietary iron absorption is increased. Thus, increased IRP-binding activity represents
decreased body iron stores [28].
Figure 1. Regulation of Iron Balance
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The hepcidin model: Liver hepcidin is a 25-amino-acid cysteine-rich peptide. Numerous
factors contribute to the regulation of hepcidin level. Liver iron levels, inflammation, hypoxia,
and anemia can be counted among these factors. Hepcidin regulates the rate of iron absorption
by controlling the expression of ferroportin-1 at basolateral membranes of enterocytes.
Internalization of ferroportin-1 and loss of its function occur after the binding of hepcidin to
ferroportin-1. Ferroportin-1 molecules take place also in macrophages and liver. Hence, it is
suggested that iron release from intestinal crypt cells, liver, and macrophages is reduced, when
hepcidin levels are increased in iron overload or inflammation (via IL-6). In contrast, it is likely
that ferroportin-1 expression and iron release is increased when hepcidin levels are reduced
as is the case in ID, anemia or hypoxia [34].
Iron released into the circulation binds to Tf and is transported to sites of use and storage.
Three forms of Tf can be found in plasma: apo-transferrin that contains no iron, monoferric-
transferrin, and diferric-transferrin. About 30–40% of these iron-binding Tf sites are occupied
under normal physiological conditions. Tf-bound iron is the most important dynamic iron pool
[35]. Tf-bound iron enters into target cells, mainly erythroid cells, but also immune and hepatic
cells via a process of receptor-mediated endocytosis [28]. Tf binds to receptor, which is called
TfR and located on the plasma membrane. Siderosomes, clathrin-coated endosomes, are
formed by invagination of Tf and receptor–ligand complexes at the cell-surface membrane [35].
After that, the siderosomes are acidified by an ATP-dependent proton influx. This process
leads to conformational changes in Tf and TFR1, and promotes iron release of Fe3+ from Tf.
Then, Fe3+ is converted to Fe2+ through a ferri-reductase and moved to the cytoplasm by the
DMT-1, while the TfR is appraised at the cell membrane again and Tf is drained back to the
circulation [28, 36]. Production of hemoglobin by the erythron accounts for most iron use.
High-level expression of TfR1 in erythroid precursors ensures the uptake of iron into this
compartment.
Hemoglobin iron has an important cycle, as aging erythrocytes undergo phagocytosis. In the
phagocytic vesicles of reticuloendothelial system macrophages, heme is metabolized through
heme oxygenase-1 (HO-1). Then, iron is released to the cytoplasm by natural-resistance-
associated macrophage protein-1, a transport protein similar to DMT-1. Macrophages are also
able to gain iron from other apoptotic cells and bacteria [1]. Iron is stored in two forms in the
cell: as ferritin in the cytosol and as hemosiderin originated from degradation of ferritin within
the lysosomes. Hemosiderin is a very small part of body iron stores. It is found mostly in
macrophages and increases in iron overload [35]. Iron export from macrophages to Tf is
accomplished primarily by ferroportin-1, the same iron-export protein expressed in duodenal
enterocytes, and hephaestin [28] (Figure 1). The amount of iron required for daily production
of 300 billion RBCs (20–30 mg) is mostly provided by recycling of iron by macrophages [1].
The liver is a major storage organ of iron, in which excess iron is stored as ferritin and
hemosiderin. The uptake of Tf-bound iron by the liver from plasma is mediated by TfR1 and
TfR2. In iron overload states, Tf is saturated and redundant iron is found in the form of non-
Tf-bound iron. This form of iron is transported along with the hepatocyte membrane through
a carrier-mediated process compatible with DMT-1. The hepatocytes can also warehouse iron
as ferritin, hemoglobin–haptoglobin complexes, and heme–hemopexin complexes. Whereas,
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ferroportin-1 is known to be the only protein that mediates the iron transport from hepatocytes.
Iron is oxidized by ceruloplasmin and attached to Tf after being released from hepatocytes [1,
28] (Figure 1).
Iron is also found at mucosal surfaces as lactoferrin. In addition to these proteins, an additional
fraction of free iron is present in the form of the labile iron pool within cells.
4. Possible mechanisms of iron deficiency in H. pylori infection
The mechanisms by which H. pylori infection contributes to IDA remain unclear. Several
studies have suggested different biologic mechanisms by which infection with H. pylori may
induce depletion in the iron stores of the host. Four explanations can be posted: 1) overt or
occult blood loss due to gastroduodenal lesions [37]; 2) decreased iron absorption due to hypo-
or achlorhydria [38]; 3) increased iron consumption by H. pylori [39]; and 4) iron sequestration
into the gastric mucosa [40,Table 2].
Mechanism Findings
Blood loss Peptic ulcer diseases
Gastric carcinoma
Gastric lymphoma
Chronic erosive esophagitis,
Chronic erosive gastritis
Chronic erosive duodenitis
Malabsorption of iron Atrophic gastritis
Reversible hypoclorhydria
Bacterial competition for iron
Changing molecular mechanisms
in iron metabolism
Elevated hepcidin level
Decreased hemeoxygenase-1
Mislocalization of transferrin receptor
Table 2. Possible Mechanisms of Iron Deficiency in Helicobacter pylori Infection
4.1. Blood loss from gastrointestinal lesions
Blood loss is the most important cause of iron deficiency in adults. Each milliliter of blood loss
(if Hb is 15 g/dL) results in loss of 0.5 mg of iron approximately. Gastrointestinal blood loss is
the most important cause in postmenopausal women and men. While menstrual blood loss
commonly causes IDA in premenopausal women, coexistent gastrointestinal lesions have
often been identified [3].
IDA resulting from gastrointestinal bleeding is a common feature of many gastrointestinal
conditions. The most common cause of upper gastrointestinal bleeding is peptic ulcer bleeding,
which is responsible for about 50% of all cases, followed by esophagitis and erosive disease [41].
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H. pylori infection is associated with both duodenal and gastric ulcer disease. Subjects infected
with H. pylori have an average lifetime risk of 10–20% for the occurrence of peptic ulcer disease.
This risk is at least three- to fourfold higher than in noninfected individuals. The bacteria can
be determined in 90–100% of subjects with duodenal ulcer and in 60–100% of subjects with
gastric ulcer. Individuals infected with bacterial strain producing a cytotoxin, or owning
cytotoxin-associated gene A (cagA), have a higher risk of development of peptic ulcer disease.
Other factors affecting the risk of peptic ulcer disease in infected individuals are amount of
gastric acid production, gastric metaplasia in the duodenal bulb, smoking, and genetic factors
(e.g., blood group O and lack of the secretor gene) [42]. Testing for H. pylori is recommended
in all patients with peptic ulcer bleeding [43]; eradication therapy for those who are H. pylori-
positive and then evaluation of the effect of this therapy. Retreatment with subsequent regimen
should also be considered in the patients who had eradication failure. The effectiveness of
eradication treatment and maintenance antisecretory therapy for the prevention of rebleeding
has been evaluated in several studies. A meta-analysis showed that H. pylori eradication group
had significantly decreased risk of rebleeding; even when only patients with successful H.
pylori eradication were evaluated, the rebleeding rate was found significantly lower [44]. Thus,
confirmation of eradication should be tested. Diagnostic tests for H. pylori have a low negative
predictive value in case of active bleeding [45]. Thus, initial negative results on biopsies
obtained in the acute setting should be judged with caution and repetition of the test during
follow-up is recommended [43].
Gastric carcinoma is also one of the important causes of gastrointestinal bleeding accounting
for nearly 4–8% of all cases [46]. The most common histopathological features of gastric
malignancies are adenocarcinoma and lymphoma of mucosa- associated lymphoid tissue
(MALT). Approximately 90% of gastric tumors are adenocarcinoma, whereas gastric MALT
lymphomas are considerably less common (approximately 3% of all gastric tumors) [47]. H.
pylori infection plays an important carcinogenic role in both gastric carcinoma and MALT
lymphoma [48]. It has been calculated that the risk for gastric adenocarcinoma and MALT
lymphoma is three- to sixfold higher in H. pylori-infected individuals than those who are
noninfected [47]. Because of the strong association between gastric cancer and H. pylori
infection, the World Health Organization (WHO) classified H. pylori as a class I carcinogen in
1994 [49]. In gastric carcinogenesis, host-related genetic elements such as a pro-inflammatory
cytokine profile and/or a positive family history as well as bacterial virulence factors play
important roles. Furthermore, environmental factors, like nutrition, and socioeconomic factors
are suggested to be also important. After the initiation by H. pylori and the influence of variable
environmental and host factors, chronic active gastritis may progressively evolve to atrophic
gastritis and intestinal metaplasia. In some individuals, the metaplastic epithelium will
undergo further genomic and phenotypic changes, resulting in gastric dysplasia and eventual
adenocarcinoma [50]. The “test and treat” strategy for H. pylori infection should be considered
effective for prevention of gastric carcinoma only in communities with a high incidence of
gastric carcinoma [51].
H. pylori has been identified as causative agent for chronic erosive gastritis, erosive esophagitis,
and erosive duodenitis [52-54]. These lesions are also among the important causes of occult
gastrointestinal bleeding [3].
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4.2. Decreased iron absorption secondary to hypo- or achlorhydria
Iron malabsorption is one of the most important causes of IDA. Decreased iron absorption
may result  from intestinal  mucosal  disorders  (most  frequently,  celiac  disease),  impaired
gastric acid secretion (including use of proton pump inhibitors), and gastric/intestinal bypass
procedures [3].
As mentioned above, nonheme ferric iron is required to be reduced to a ferrous form before
its absorption in the duodenum and first jejunum. Gastric acid has an important role in
reducing and solubilizing the inorganic form of the iron [30]. Ferric iron has been demonstrated
to be insoluble and precipitates at pH above 3 [55]. Thus, IDA can develop in patients with
hypochlorhydria because of gastric surgery or atrophic body gastritis [56, 57].
Atrophic body gastritis is characterized by atrophy of the gastric body mucosa, hypergastri‐
nemia, and hypo-achlorhydria [58]. Atrophy is a time-related phenomenon and H. pylori
infection is considered an etiologic factor in the development of atrophic body gastritis [59].
This can eventually lead to loss of gastric glands and development of multifocal atrophic
gastritis, which is often accompanied by intestinal metaplasia. A steady increase in the
prevalence of atrophy and metaplasia is seen with advancing age [60]. As with peptic ulcer
disease, the chance for development of atrophic body gastritis depends on the severity of
gastritis and the characteristics of the bacterial strain [59]. Another interesting factor that can
influence the development of atrophic body gastritis is H. pylori lipopolysaccharide mimicking
Lewis x and y antigens. The presence of cross-reacting antibodies against the antigens and the
gastric mucosa may have a great chance to develop atrophy [61]. Atrophic body gastritis may
improve on long-term follow-up after H. pylori eradication, which is thus strongly recom‐
mended in atrophic gastritis [62].
It is well known that H. pylori infection induces gastric acid hyposecretion irrespective of
presence of fundus atrophy when affecting the gastric body [63]. Also, H. pylori gastritis has
been demonstrated to be associated with a reversible reduction in the ascorbic acid levels of
gastric juice [64]. Therefore, a diffuse H. pylori-gastritis could decrease iron absorption by
altering the physiological gastric secretion, even if it is mild [65].
4.3. Increased iron uptake and utilization by bacteria
H. pylori has been shown as a causative agent in IDA that is not attributable to usual reasons
such as intestinal losses or poor intake, malabsorption or diversion of iron in the reticuloen‐
dothelial system, and unresponsive to iron therapy. The possible mechanism may be explained
via bacterial competition for dietary iron.
Iron is an essential trace element in all organisms, even for pathogenic bacteria. Acquisition of
iron by H. pylori from the host is necessary for colonization and infection [66]. Intracellular
bacterial iron is exactly regulated and kept at an optimal level. Mostly, the free iron in the host
is found to be complexes with proteins such as Tf and lactoferrin on mucosal surfaces. Thus,
the available extracellular host iron is at a very low level. Therefore, bacterial pathogens such
as H. pylori have to develop some mechanisms to compete for the restricted extracellular iron
in the host to survive and maintain disease [67, 68].
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In the gastric mucosa, iron is available as lactoferrin, heme compounds arising from damaged
tissues, and iron based on pepsin-degraded food. Iron represents increased solubility in the
acidic fluid, and iron-complexing proteins of eukaryotic organisms exhibit lower binding
capacity under the acidic conditions in gastric juice.
H. pylori produce several iron transport proteins and iron storage proteins [69-72,Table 3].
Fe2+ is the main form of free iron in the gastric medium, and H. pylori keeps this ferrous ion
through the FeoB protein [73]. FeoB-mediated iron acquisition has great importance for H.
pylori. It has been shown that isogenic FeoB mutant mice could not colonize the gastric mucosa
[73]. Ferric reductase activity for conversion of Fe3+ to Fe2+ is transported by the FeoB system
of H. pylori [74].
Function Protein
Enzyme Ferri-reductase
Hemeoxygenase-1 (HugZ)
Transport FeoB
FecA (ferric citrate outer membrane receptor)
FecD (inner membrane permease)
FecE (ATP-binding protein)
FrpB (outer membrane receptor)
CeuE (periplasmic-binding protein)
Iron repressible outer membrane proteins (IROMPs)
Lactoferrin-binding protein
Siderophore
Storage Pfr-ferritin
Helicobacter pylori-neutrophil-activating protein-(HP-NAP)-
Bacterioferritin
Table 3. Proteins Involved in Iron Acquision System of Helicobacter pylori
Additionally, H. pylori also has various transport systems for ferric iron [72, 75]. Since the ferric
iron is insoluble, its transport needs an outer membrane receptor to transport the iron over the
outer membrane. H. pylori has three copies of the ferric citrate outer membrane receptor FecA
and three copies of the FrpB outer membrane receptor [69-72]. There are two copies of the
periplasmic-binding protein CeuE and finally a single inner membrane permease (FecD) and
an ATP-binding protein (FecE). ABC transporter system transports the iron from the periplasm
to the cytoplasm [73].
Subsequently, specific outer membrane receptor proteins bind the iron. It has been suggested
that heme-iron-repressible outer membrane proteins (IROMPs) are involved in heme binding
and/or uptake by H. pylori [39]. When the heme is located in the cytoplasm, it can be used by
a heme oxygenase protein. Heme oxygenase catalyzes the NADPH-reductase-dependent
degradation of heme to biliverdin, which is the rate-limiting step leading to the release of iron
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and carbon monoxide. Some researchers have identified a heme oxygenase protein called
HugZ that is responsible for heme iron utilization in H. pylori [76].
A common iron acquisition system present in many pathogens is the secretion of low-
molecular-mass, high-affinity iron chelators, which are called siderophores. These chelators
are able to remove iron from Tf or lactoferrin [77-78].
Two iron storage proteins in H. pylori have been characterized, the Pfr ferritin and H. pylori
neutrophil-activating protein (HP-NAP) bacterioferritin. The 19-kDa Pfr ferritin serves as an
intracellular iron deposit and protects H. pylori against iron toxicity and free iron-mediated
oxidative stress [79-83]. Iron-binding Pfr ferritin can be delivered and reused to maintain
growing up in the iron-limited states [83]. HP-NAP was isolated from neutrophilic granulo‐
cytes as an immuno-dominant protein in vitro [84]. It was demonstrated to mediate adhesion
of H. pylori to mucin [85]. The HP-NAP protein is similar to bacterioferritins [86, 87]. Although
it is suggested, a role of HP-NAP in H. pylori iron storage is yet to be demonstrated [87].
In addition, lactoferrin-binding protein has been suggested to be highly specific for human
lactoferrin in H. pylori infection [40].
All these mechanisms suggest that H. pylori utilize the iron from host and use or store for
colonization and growth.
4.4. Changing molecular mechanisms in iron metabolism
H. pylori may act in changing molecular mechanisms that play a role in iron metabolism.
The best evaluated molecule in the association between H. pylori and ID is hepcidin. Hepcidin
is a protein that is secreted into the blood and interacts with villous enterocytes to regulate the
rate of iron absorption by controlling the expression of ferroportin-1. When hepcidin is
increased, iron release from enterocytes is reduced. The anemia of chronic inflammation is
mediated, in part, by the stimulation of hepcidin by cytokines [35]. Hepcidin has been reported
to be elevated in patients infected with H. pylori, acting as an acute-phase reactant in response
to the inflammation produced in the gastric mucosa and resulting in a pathology known as
“anemia of inflammation or chronic disease” [88-90]. Prohepcidin, hepcidin's precursor, was
also shown to increase in H. pylori infection and is decreased after eradication of H. pylori
infection [91].
HO-1 is an enzyme that is responsible in heme degradation in host enterocytes. H. pylori may
affect levels of HO-1. A significant increase in Keap1 gene expression was found in transfected
AGS cells with H. pylori HspB. The increase in Keap1 was associated to decreased antioxidant
enzymes including HO-1, and phase II detoxifying enzyme NAD(P)H:quinone oxidoreduc‐
tase-1 [92]. CagA status is suggested to be important in this action of H. pylori. HO-1 is also
found to be down-regulated in gastric epithelial cells of patients infected with cagA-positive
H. pylori but not in gastric epithelial cells of patients infected with cagA-negative H. pylori [93].
TfR1 and TfR2 on cell surface mediate the cellular uptake of Tf-bound iron from plasma [28].
H. pylori is known to affect host cell polarity and intracellular trafficking [94]. In H. pylori-
infected cell lines, it has been shown that Tfr was mislocalized to sites of H. pylori microcolony
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growth at the apical cell surface. H. pylori colonization of the polarized epithelium has been
shown to lead to increased apical release of Tf [95].
5. Factors that affect iron deficiency development in H. pylori infection
Although H. pylori gastric infection has been shown to be strongly associated with IDA, it is
only a small portion of patients with H. pylori gastritis that develop IDA. The main question
is why only a small portion of patients with H. pylori gastritis develop IDA, and what differ‐
entiates these patients.
The pattern of H. pylori-related gastritis is a significant predictor of the results of infection, and
it determines the different effects of the bacteria on gastric functions. The panelists of the
updated Sydney system suggested that most individuals infected with H. pylori develop a more
evident inflammation in the antrum (nearly double) compared to the corpus in the absence of
atrophy [96].
The relationship between chronic gastritis and gastric acid secretion is strictly dependent on
the topography of gastric inflammation [97]. It has been demonstrated that gastritis in the
corporal mucosa leads to decreased acid secretion with a consequent increase in intragastric
pH [98]. Severity of inflammation is also important in terms of clinical outcomes.
Additionally, H. pylori strains owning the cagA or the vacuolating cytotoxin A (vacA), which
are highly virulent, display potent mechanisms to produce or magnify ID in patients compar‐
ing less virulent strains [99, 100]. For example, Baysoy et al. have reported that cagA-positive
strains was associated with a greater decrease in gastric juice ascorbic acid compared to cagA-
negative strains [101]. Tan et al. reported that cagA and vacA contribute to iron uptake from
gastric epithelial cells in a cooperative manner. VacA induces apical mislocalization of TfR.
CagA alters internalization and intracellular transport of TfR. These pathogenic factors take
away iron from holo-transferrin of host and maintain colonization on the gastric epithelial cell
surface [95]. Moreover, Cardenas et al. found that patients infected with the cagA-positive
strains did not improve their ferritin levels after eradication treatment as much as those who
were cagA-negative [102].
6. Management of iron deficiency in H. pylori infection
Like other hematological conditions such as MALT lymphoma, vitamin B12 deficiency, and
idiopathic thrombocytopenic purpura, IDA is also included in the international consensus and
guidelines as an indication for “test and treat” of H. pylori [51, 62, 103,Table 4]. Whereas, it
should not substitute the other workup for IDA. The endoscopic evaluations for upper and
lower gastrointestinal tracts in men and postmenaposal women, celiac serology should be
performed in cases of IDA.
Extradigestive Manifestations of Helicobacter Pylori Infection - An Overview124
Hematological Condition Level of Evidence
MALT lymphoma Evidence level: 1a Grade of recommendation: A
IDA Evidence level: 1aGrade of recommendation: A
Idiopathic thrombocytopenic purpura Evidence level: 1bGrade of recommendation: A
Vitamin B12 deficiency Evidence level: 3bGrade of recommendation: B
Abbrevations: Grades of recommendations and evidence levels in support of recommendations
Grade of recommendation: A; Evidence level: 1a: Systematic review of randomized controlled trial (RCT) of goog
methodological quality and with homogeneity
Grade of recommendation: A; Evidence level: 1b: Individual RCT with narrow CI
Grade of recommendation: B; Evidence level: 3b: Individual case-control study
Table 4. Evidence Based Relationship between H. pylori and the Etiology of other Hematological Conditions (in these
disorders, H. pylori should be sought and eradicated)
It is possible to rescue hematological and ferro-kinetic parameters after H. pylori eradication.
Its implication as an unexplained origin of ID was revealed in the international consensus and
management guidelines of H. pylori infection. It should be tested and eradicated in both adults
and children with unexplained origin of ID [104,105].
There has not been any concensus on the treatment of IDA in H. pylori-infected patients yet.
Three meta-analyses evaluated the effect of H. pylori eradication on IDA. Qu et al. reported
that eradication of H. pylori improved hemoglobin and serum ferritin levels but not signifi‐
cantly [27]. Whereas, Huang et al. reported another meta-analysis of 8 randomized controlled
trials (RCTs) in which five RCTs had used PPI-based triple therapy and three RCTs had used
bismuth-based triple therapy as eradication regimens. They found that anti-H. pylori treatment
combined with iron supplement was more effective than iron administration alone in the
treatment of IDA in H. pylori-infected patients. They also showed that bismuth-based triple
therapy had an advantage over PPI-based triple therapy [26]. However, this finding needs to
be confirmed. In another meta-analysis involving 956 patients and 16 RCTs in which 13 RCT
had used PPI-based triple treatment and 3 RCT used bismuth-based triple treatment, it was
shown that the increase in Hb, serum iron, and serum ferritin levels were significantly higher
with anti-H. pylori treatment plus oral iron compared with oral iron alone in patients with
documented H. pylori infection and IDA [24]. Recently in a study by Habib et al., sequential
and standard therapies were compared in children. It was shown that there was no significant
difference in H. pylori eradication success between two groups and there was no significant
relationship between eradication treatment and serum ferritin levels [106].
In conclusion, refractoriness to oral iron treatment and unexplained IDA may justify a “test-
and-treat” approach of H. pylori eradication as recommended by the Maastricht IV European
Consensus Conference [62], Second Asia–Pacific Consensus Guideline [51], and the III
Working Group Consensus Report 2015 [103]. Standard treatment regimens that are recom‐
mended in dyspeptic patients by current guidelines combined with iron supplement are
effective in IDA in patients with H. pylori infection. These eradication regimens are listed in
Table 5 based on current guidelines [Table 5,51, 62, 103].
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First-line therapy Duration Drugs and doses
Standard PPI-based triple therapy 7-14days
PPI 2x1
+ Amoxicillin 1g 2x1
+ Clarithromycin 500 mg 2x1
or
(in the presence of penicillin allergy)
PPI 2x1
+ Metronidazole 500 mg 2x1
+Clarithromycin 500 mg 2x1
or
(in areas of low clarithromycin resistance)
PPI 2x1
+ Amoxicillin 1 g 2x1
+ Metronidazole 400 mg 2x1
First 5 days PPI 2x1 + Amoxicillin 1 g 2x1
Sequential therapy PPI 2x1
Followed by 5 days + Metronidazole or tinidazole 500 mg 2x1+ Clarithromycin 500 mg 2x1
Concomitant therapy
(non-bismuth quadruple) 10 days
PPI 2x1
+ Amoxicillin 1g 2x1
+ Metronidazole or tinidazole 500mg 2x1
+ Clarithromycin 500 mg 2x1
Second-line therapy Duration Drugs and doses
*Bismuth-containing quadruple therapy
(when bismuth is available) 7–14 days
PPI 2x1
+ Bismuth salts 4x1 or 2x2
+ Tetracycline, 500mg 3x1
+ Metronidazole, 500mg 3x1
Levofloxacin-containing triple therapy 10 days
PPI 2x1
+ Amoxicillin 1g 2x1
+ Levofloxacin, 500mg 1x1 or 250mg 2x1
or
(in the presence of penicillin allergy)
PPI 2x1
+ Clarithromycin 500 mg 2x1
+ Levofloxacin, 500mg 1x1 or 250mg 2x1
Rifabutin-based triple therapy: 7–10 days
PPI 2x1
+Rifabutin 150 mg 2x1
+Amoxicillin 1 g 2x1
Third-line therapy
After failure of second-line therapy, treatment should be guided by antimicrobial susceptibility testing, whenever possible
*In areas of high clarithromycin resistance, bismuth-containing quadruple therapy is recommended for first-line em‐
pirical treatment.
Abbrevations: PPI: Proton pump inhibitor
Table 5. Treatment regimens recommended for first- and second-line therapy of Helicobacter pylori infection
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7. Summary
Iron is an essential element for all living organisms. Iron metabolism is controlled mainly by
absorption. ID is the most common nutritional deficiency and causes clinically important
outcomes. One of the most common results of ID is IDA. ID results from increased physio‐
logical needs, blood losses, inadequate intake, and diminished absorption. H. pylori infection
is one of the important causes of IDA especially in undetermined and refractory cases.
In the literature case series, sero-epidemiological studies and meta-analysis showed strong
evidence regarding the relationship between IDA and H. pylori. Several mechanisms have been
proposed for IDA in H. pylori infection. First, blood loss from gastrointestinal lesions related
with H. pylori; second, malabsorption due to hypo- or achlorhydria resulting from gastric body
inflammation and atrophy; third, bacterial competition for dietary iron with several mecha‐
nisms; and last, changing regulatory pathways especially hepcidin levels in iron metabolism
by the bacteria.
Although H. pylori infection is more prevalent, frequency of IDA related with H. pylori is low.
Influencing factors for developing IDA in H. pylori infection include topographic distribution
of gastric inflammation, severity of inflammation, virulence factor of the bacteria.
Once IDA is diagnosed in H. pylori-infected patient, other most common causes of IDA should
be evaluated carefully. Depending on “test and treat” strategy, the H. pylori infection should
be eradicated based on recommendations by the current guidelines.
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